News Conference News AHA 2025 Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials Yael L. Maxwell November 13, 2025
News Conference News THT 2025 Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Todd Neale February 12, 2025
News Conference News ESC Heart Failure 2023 More ARNI Insights Fortify Role in ‘Below Normal’ LVEF: PARAGLIDE-HF Shelley Wood May 22, 2023
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News ESC Heart Failure 2021 Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR Shelley Wood July 06, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020
News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News ESC 2019 PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen Todd Neale September 01, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019